Breaking the picomolar barrier in lateral flow assays using Bright-Dtech 614-Europium nanoparticles for enhanced sensitivity
[EN] Lateral flow immunoassays (LFIA) are among the most widely used rapid diagnostic tests for point-of-care screening of disease biomarkers. However, their limited sensitivity hinders their use in complex clinical applications that require accurate biomarker quantification for precise medicine. To...
| Autores: | , , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de publicación: | 2025 |
| País: | España |
| Recursos: | Universitat Politècnica de València (UPV) |
| Repositorio: | RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia |
| Idioma: | inglés |
| OAI Identifier: | oai:dnet:riunet______::f56144ea150bafa5a4da4536ed44855f |
| Acesso em linha: | https://riunet.upv.es/handle/10251/235235 |
| Access Level: | acceso embargado |
| Palavra-chave: | Lanthanides Fluorescent nanoparticles Lateral flow immunoassay Lactate dehydrogenase Point of care |
| Resumo: | [EN] Lateral flow immunoassays (LFIA) are among the most widely used rapid diagnostic tests for point-of-care screening of disease biomarkers. However, their limited sensitivity hinders their use in complex clinical applications that require accurate biomarker quantification for precise medicine. To address this limitation, we evaluated Bright-Dtech¿-614 Europium nanoparticles to enhance LFIA assay sensitivity. These nanoparticles exhibited a luminescence quantum yield of 70¿% and a 90¿% conjugation efficacy with antibodies by direct adsorption. Considering these properties, we developed an LFIA to quantify human lactate dehydrogenase (h-LDH), a biomarker and therapeutic target in cancer disease. The Bright-Dtech¿-614 Eu nanoparticle-based assay achieved a detection limit of 38¿pg¿mL¿1, representing a 686-fold, 15-fold, and 2.9-fold improvement in sensitivity over conventional LFIA platforms using gold (AuNPs), carbon nanoparticles, and standard ELISA, respectively. The assay exhibited strong accuracy, with a mean recovery rate of 108¿±¿11¿%, and demonstrated excellent reproducibility, as evidenced by inter- and intra-batch RSD values of 4.9¿% and 9.7¿%, respectively, when testing LDH-spiked serum samples. By substituting traditional gold nanoparticles with the Bright-Dtech¿-614 Eu nanoparticles, we achieved detection limits in the femtomolar range, significantly broadening the applicability of LFIA for precision medicine. |
|---|